JPWO2020135201A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020135201A5 JPWO2020135201A5 JP2021528872A JP2021528872A JPWO2020135201A5 JP WO2020135201 A5 JPWO2020135201 A5 JP WO2020135201A5 JP 2021528872 A JP2021528872 A JP 2021528872A JP 2021528872 A JP2021528872 A JP 2021528872A JP WO2020135201 A5 JPWO2020135201 A5 JP WO2020135201A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- cdr
- light chain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811617535 | 2018-12-28 | ||
| CN201811617535.8 | 2018-12-28 | ||
| PCT/CN2019/126495 WO2020135201A1 (zh) | 2018-12-28 | 2019-12-19 | 一种抗体及其用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022515318A JP2022515318A (ja) | 2022-02-18 |
| JPWO2020135201A5 true JPWO2020135201A5 (enExample) | 2023-07-28 |
| JP7562528B2 JP7562528B2 (ja) | 2024-10-07 |
Family
ID=71126071
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021528872A Active JP7562528B2 (ja) | 2018-12-28 | 2019-12-19 | 抗体及びその用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12297265B2 (enExample) |
| EP (1) | EP3904386A4 (enExample) |
| JP (1) | JP7562528B2 (enExample) |
| KR (1) | KR20210109520A (enExample) |
| CN (2) | CN113166246B (enExample) |
| WO (1) | WO2020135201A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020135201A1 (zh) | 2018-12-28 | 2020-07-02 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
| KR20210134321A (ko) | 2019-02-01 | 2021-11-09 | 노바록 바이오테라퓨틱스 리미티드 | 항-클라우딘 18 항체 및 이의 이용 방법 |
| EP4151235A4 (en) * | 2020-05-15 | 2025-08-06 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | ANTIBODY-DRUG CONJUGATE, ITS PREPARATION METHOD AND ITS USE |
| CN111704669B (zh) * | 2020-07-13 | 2022-05-13 | 北京凯因科技股份有限公司 | 一种用于治疗晚期胃癌的抗cldn18全人源化抗体 |
| EP4217396A4 (en) * | 2020-09-28 | 2025-06-18 | Elpiscience (Suzhou) Biopharma, Ltd. | NEW ANTI-CLAUDIN18 ANTIBODIES |
| CN114437221B (zh) * | 2020-11-05 | 2023-08-01 | 北京天广实生物技术股份有限公司 | 一种癌症检测抗体及其用途 |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| CN114617961B (zh) * | 2020-12-10 | 2022-12-02 | 北京东方百泰生物科技股份有限公司 | 一种抗lag-3单克隆抗体的注射制剂 |
| PE20231561A1 (es) | 2020-12-23 | 2023-10-03 | Sotio Biotech A S | Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2 |
| CN115109154A (zh) * | 2021-03-17 | 2022-09-27 | 三优生物医药(上海)有限公司 | 一种靶向cldn18.2的抗体或其抗原结合片段及其应用 |
| US12577320B2 (en) | 2021-05-08 | 2026-03-17 | Remegen Co., Ltd. | Anti-Claudin 18.2 antibody and antibody-drug conjugate thereof |
| CN115611983A (zh) * | 2021-07-14 | 2023-01-17 | 三优生物医药(上海)有限公司 | Cldn18.2结合分子及其用途 |
| CN113801231B (zh) * | 2021-08-20 | 2022-09-02 | 四川大学华西医院 | 抗dog-1抗体或其抗原结合片段及其用途 |
| CN113687085A (zh) * | 2021-08-27 | 2021-11-23 | 复旦大学附属中山医院 | 一种评估实体肿瘤Claudin18.2蛋白表达的方法和应用 |
| AU2022371521A1 (en) * | 2021-10-19 | 2024-05-02 | Biosion Inc. | Antibodies binding cldn18.2 and uses thereof |
| CN115991784A (zh) * | 2021-10-19 | 2023-04-21 | 宝船生物医药科技(上海)有限公司 | 抗cd47-cldn18.2双特异性抗体及其用途 |
| CA3242970A1 (en) * | 2021-12-17 | 2023-06-22 | Fortvita Biologics (Singapore) Pte. Ltd. | ANTIBODY-DRUG CONJUGATE TARGETING CLAUDINE 18.2 |
| KR102809807B1 (ko) * | 2021-12-21 | 2025-05-16 | 한림대학교 산학협력단 | 항-cldn18.2를 포함하는 키메릭 항원 수용체를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물 및 이의 제조 방법 |
| CN117229398A (zh) * | 2022-06-15 | 2023-12-15 | 中山康方生物医药有限公司 | 抗cldn18.2抗体、其药物组合物及用途 |
| CN116284387B (zh) * | 2022-07-15 | 2025-10-03 | 台州恩泽医疗中心(集团) | 一种抗hla-g2及hla-g6分子的单克隆抗体及用途 |
| WO2024020236A2 (en) * | 2022-07-22 | 2024-01-25 | The United States Government, As Represented By The Secretary Of The Army | Monoclonal antibodies that interfere with iron uptake |
| CN117777288A (zh) * | 2022-09-29 | 2024-03-29 | 南京博望医药科技有限公司 | 抗密蛋白18.2的抗体 |
| WO2024074145A1 (zh) * | 2022-10-08 | 2024-04-11 | 盛禾(中国)生物制药有限公司 | 一种结合baffr和cd3的双特异性抗体及其应用 |
| CN115947851B (zh) * | 2022-12-19 | 2024-02-13 | 华润生物医药有限公司 | 结合cldn18.2的抗体及其用途 |
| TW202434307A (zh) | 2023-01-18 | 2024-09-01 | 大陸商泰勵生物科技（上海）有限公司 | 抗體偶聯藥物及其用途 |
| CN116813782B (zh) * | 2023-08-10 | 2024-01-23 | 北京百普赛斯生物科技股份有限公司 | 一种Claudin-18.2特异性抗体及其应用 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| CN117106081B (zh) * | 2023-09-28 | 2024-05-07 | 北京凯祥弘康生物科技有限公司 | 一种抗nfl蛋白的捕获抗体 |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025078686A1 (en) | 2023-10-12 | 2025-04-17 | Sotio Biotech A.S. | Combination therapy involving antibody-drug conjugates against claudin18.2 and pd1/pd-l axis inhibitors for treatment of cancer |
| CN117736329B (zh) * | 2023-12-25 | 2024-11-12 | 华润生物医药有限公司 | 抗pd-1抗体及其用途 |
| CN118184782A (zh) * | 2024-03-13 | 2024-06-14 | 河北森朗生物科技有限公司 | 抗cldn18.2的纳米抗体、嵌合抗原受体及其应用 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6051228A (en) * | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| JP3523245B1 (ja) | 2000-11-30 | 2004-04-26 | メダレックス，インコーポレーテッド | ヒト抗体作製用トランスジェニック染色体導入齧歯動物 |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| EP1997832A1 (en) | 2007-05-29 | 2008-12-03 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| US9056092B2 (en) | 2011-12-02 | 2015-06-16 | Ethicon, Inc. | Hemostatic bioabsorbable device with polyethylene glycol binder |
| WO2013167153A1 (en) | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| WO2013174404A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174403A1 (en) | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| NZ746691A (en) | 2012-11-13 | 2020-08-28 | Astellas Pharma Inc | Agents for treatment of claudin expressing cancer diseases |
| WO2014075697A1 (en) * | 2012-11-13 | 2014-05-22 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| WO2014146672A1 (en) | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| KR102236367B1 (ko) | 2013-07-26 | 2021-04-05 | 삼성전자주식회사 | DARPin을 포함하는 이중 특이 키메라 단백질 |
| AU2015232352B2 (en) | 2014-03-17 | 2021-02-18 | Mitsubishi Tanabe Pharma Corporation | Antibody-fynomer conjugates |
| WO2016165762A1 (en) | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2017059900A1 (en) * | 2015-10-07 | 2017-04-13 | Biontech Cell & Gene Therapies Gmbh | Antigen receptors and uses thereof |
| ES2979068T3 (es) * | 2016-07-08 | 2024-09-24 | Crage Medical Co Ltd | Anticuerpos para anti-claudina 18A2 y utilización de los mismos |
| WO2018054484A1 (en) | 2016-09-23 | 2018-03-29 | Biontech Ag | Bispecific trivalent antibodies binding to claudin 6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases |
| EP4667495A3 (en) | 2017-12-15 | 2026-03-11 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Bioactive molecule conjugate, preparation method and use thereof |
| WO2019149116A1 (zh) | 2018-01-30 | 2019-08-08 | 四川科伦博泰生物医药股份有限公司 | 制备偶联物的方法 |
| WO2019154120A1 (zh) | 2018-02-11 | 2019-08-15 | 四川科伦博泰生物医药股份有限公司 | 细胞毒性剂及其偶联物、其制备方法及用途 |
| TW202003562A (zh) | 2018-03-14 | 2020-01-16 | 中國大陸商北京軒義醫藥科技有限公司 | 抗密連蛋白18.2(cldn18.2)抗體 |
| SG11202007074PA (en) | 2018-05-18 | 2020-08-28 | Lanova Medicines Ltd Company | Anti-claudin 18.2 antibodies and uses thereof |
| CN111867630B (zh) | 2018-06-17 | 2023-10-13 | 上海健信生物医药科技有限公司 | 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用 |
| CN111110862A (zh) | 2018-11-01 | 2020-05-08 | 上海健信生物医药科技有限公司 | 抗cldn18．2抗体的药物偶联体及其制备方法和用途 |
| CN112770723B (zh) | 2018-07-25 | 2024-08-02 | 阿克罗斯生物科学公司 | Cldn 18.2特异性单克隆抗体及其使用方法 |
| SG11202105885WA (en) | 2018-12-07 | 2021-07-29 | Zlip Holding Ltd | Anti-claudin antibodies and uses thereof |
| WO2020135201A1 (zh) | 2018-12-28 | 2020-07-02 | 四川科伦博泰生物医药股份有限公司 | 一种抗体及其用途 |
-
2019
- 2019-12-19 WO PCT/CN2019/126495 patent/WO2020135201A1/zh not_active Ceased
- 2019-12-19 KR KR1020217015188A patent/KR20210109520A/ko active Pending
- 2019-12-19 CN CN201980076474.5A patent/CN113166246B/zh active Active
- 2019-12-19 JP JP2021528872A patent/JP7562528B2/ja active Active
- 2019-12-19 US US17/295,603 patent/US12297265B2/en active Active
- 2019-12-19 EP EP19903546.0A patent/EP3904386A4/en active Pending
- 2019-12-19 CN CN202411323934.9A patent/CN119350498A/zh active Pending
-
2025
- 2025-04-02 US US19/097,908 patent/US20250340630A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020135201A5 (enExample) | ||
| US12577306B2 (en) | Bispecific anti PD1-anti TIM3 antibodies | |
| JP2020510422A5 (enExample) | ||
| RU2017145150A (ru) | Антитело против pdl-1, его фармацевтическая композиция и применение | |
| JP2021531764A5 (enExample) | ||
| RU2016125551A (ru) | Биспецифические антигенсвязывающие конструкции против her2 | |
| JP2019519492A5 (enExample) | ||
| JP2017506067A5 (enExample) | ||
| JP2017511687A5 (enExample) | ||
| IL298326A (en) | Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same | |
| CN110799540A (zh) | 多特异性抗体及其制备和使用方法 | |
| JPWO2021177438A5 (enExample) | ||
| JPWO2020198009A5 (enExample) | ||
| JPWO2021063201A5 (enExample) | ||
| TW202426503A (zh) | 癌症治療中與ｐｄ－１訊息抑制劑組合之抗ｃｌｄｎ４－抗ｃｄ１３７雙特異性抗體的用途 | |
| JPWO2023143263A5 (enExample) | ||
| WO2023163087A1 (ja) | 抗変異ｃａｌｒ抗体と他の薬剤とを組み合わせてなる医薬 | |
| US20240156870A1 (en) | Anti-egfr single domain antibodies and therapeutic constructs | |
| JPWO2022152290A5 (enExample) | ||
| JPWO2022057875A5 (enExample) | ||
| JPWO2020252478A5 (enExample) | ||
| RU2025125106A (ru) | Антитела к her3/muc1 и их применения | |
| WO2024192534A1 (en) | Anti-mesothelin (msln) single domain antibodies and therapeutic constructs | |
| JP2025525408A (ja) | 二重特異性抗体及びその応用 | |
| AU2023259611A1 (en) | Modified cytotoxic t cells and methods of use thereof |